Compare SKYT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | NRIX |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2021 | 2020 |
| Metric | SKYT | NRIX |
|---|---|---|
| Price | $35.85 | $17.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $26.50 | ★ $30.50 |
| AVG Volume (30 Days) | 859.2K | ★ 2.5M |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1842.86 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $442,139,000.00 | $76,987,000.00 |
| Revenue This Year | $40.16 | N/A |
| Revenue Next Year | $4.52 | $48.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 29.18 | ★ 99.31 |
| 52 Week Low | $8.49 | $8.20 |
| 52 Week High | $39.93 | $22.50 |
| Indicator | SKYT | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 57.11 |
| Support Level | $33.42 | $16.81 |
| Resistance Level | $39.93 | $17.23 |
| Average True Range (ATR) | 1.62 | 1.31 |
| MACD | -0.31 | 0.12 |
| Stochastic Oscillator | 36.18 | 63.81 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play semiconductor foundry providing foundational-node manufacturing, advanced technology development, and advanced packaging services through an integrated, multi-site operating model. It operates within the United States, with fabrication and packaging facilities in Minnesota, Texas, and Florida.l. Its segments include: Legacy SkyWater: A pure-play technology foundry that offers advanced semiconductor development and manufacturing services from its fabrication facility in Bloomington, Minnesota and advanced packaging services from its Kissimmee Florida facility; and SkyWater Texas: A high-volume manufacturer that offers manufacturing services from its fabrication facility in Austin, Texas.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.